Current antiretroviral therapy has reduced morbidity and mortality of HIV patients. However, their induced hepatotoxicity constitutes a risk. In this issue, we report a clinical case of fulminant hepatitis, observed in the HIV unit of the hepatogastroenterology department of the General hospital of Loandjili in Pointe-Noire. The patient is a 36-year-old female HIV treated with triple-dug combination antiretroviral therapies (ART) including one antiprotease (ritonavir) and two non-nucleoside reverse transcriptase inhibitors (nevirapine and efavirenz). He developed fulminant hepatitis five years after treatment initiation. He succumbed to the side effects. Although antiretroviral combination therapies are the standard of care for HIV infection, increased vigilance is warranted to early identify this side effect and adjust treatment in order to prevent fatal consequences.
References
[1]
Gervais A. ,et al. (2009)Hépatotoxicité des antirétroviraux Hépato-Gastro 16, 93-99.
[2]
Wambani, J.R., Olga, P.E., Arika, W.M., et al. (2015) Antiretroviral Drug Hepatotoxicity and Risk Factors in HIV Patients with or without Hepatitis B and C: A Review. Journal of Infectious Diseases and Therapy, 3, 258.
[3]
Labarga, P., Soriano, V., Vispo, M.E., et al. (2007) Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. The Journal of Infectious Diseases, 196, 670-676. https://doi.org/10.1086/520092
[4]
Brunon, R., Sacchi, P., Maiocchi, L., et al. (2006) Hepatotoxicity and Antiretroviral Therapy with Protease Inhibitors. A Review. Digestive and Liver Disease, 38, 363-373. https://doi.org/10.1016/j.dld.2006.01.020
[5]
Bossali, F., Gassaye, D., Atipo-Ibara, B.I., Ndziessi, G. and Ibara, J.R. (2015) Evaluation de la performance des services d’hépatogastroentérologie pour la prise en charge des cirrhotiques au Congo-Brazzaville en 2014. Journal Africain d'Hépato-Gastroentérologie, 9, 58-59. https://doi.org/10.1007/s12157-015-0593-9
